Enicepatide

Enicepatide (CT-388) is Roche's once-weekly dual GLP-1/GIP receptor agonist, the asset that justified roughly $2.7B of the Carmot Therapeutics acquisition in late 2023. Phase 1b data in obesity showed approximately 18.8% mean weight reduction at 24 weeks (reported by Roche as placebo-adjusted, though Phase 1b placebo arms are small and the delta should be re-confirmed in Phase 2), competitive with tirzepatide at comparable timepoints, which cleared the way for Roche to launch two Phase 3 trials in 2025. The commercial stakes are obvious: the global obesity drug market is projected to clear $100B annually by the early 2030s, and Roche needs a credible challenger to Lilly's Zepbound and Novo's Wegovy. [1][2][3]

Novel compound, no prior approvals anywhere. Two Phase 2 trials have completed per the registry: NCT06628362 (n=447, overweight/obese adults with type 2 diabetes, 36-week body-weight endpoint) and NCT06525935 (n=469, obesity with at least one comorbidity, 48-week body-weight endpoint). [4][5] As of this writeup's generation date, Roche has not publicly released topline results from either Phase 2 trial; the delay in a highly competitive class is itself a mild flag for investors to track. Phase 3 enrollment is active in two trials sponsored by Hoffmann-La Roche: NCT07351045 (2,000 participants, obesity without T2D) and NCT07351058 (1,600 participants, obesity with T2D), both with percent change in body weight at 72 weeks as the primary endpoint. [6][7] A Phase 1 PK ethnobridging study in Chinese adults (NCT07626515) is also recruiting, consistent with a global registrational strategy. [8] No FDA Breakthrough Therapy, Fast Track, or other designations have been publicly announced. Phase 3 readouts realistically land in 2027, with potential BLA/NDA submission in 2028 and launch in the 2028-2029 window if trials succeed and manufacturing scales.

Enicepatide activates two gut hormone receptors at once. GLP-1R (the glucagon-like peptide 1 receptor) is a G-protein coupled receptor that triggers insulin release when blood sugar rises, slows stomach emptying so meals feel bigger for longer, and dampens appetite signals in the hypothalamus. [9] GIPR (the gastric inhibitory polypeptide receptor) also drives insulin secretion and influences how fat tissue stores and releases energy. This is the same dual-agonist strategy as Eli Lilly's tirzepatide, approved as Mounjaro for T2D and Zepbound for obesity, which generated roughly $16.5B combined in 2024. [10] The mechanism is validated three ways. Human genetics: loss-of-function variants in GLP1R raise diabetes risk, gain-of-function variants protect against it. Pharmacology: single-agonist GLP-1 drugs like semaglutide and liraglutide have been lowering weight and HbA1c for a decade. [11] Head-to-head data: tirzepatide beat semaglutide in SURPASS-2 (T2D) and SURMOUNT-5 (obesity). [12] The open biology question is how much of tirzepatide's edge over pure GLP-1 drugs actually comes from GIP agonism versus more potent GLP-1 signaling. Amgen's MariTide tests the opposite hypothesis (GIP antagonism plus GLP-1 agonism), so the role of the GIP arm matters commercially even while the biology is still being argued out.

Standard registrational obesity package, modeled on Lilly's SURMOUNT and Novo's STEP programs. Both Phase 3 trials use percent change in body weight from baseline at week 72 as the primary endpoint. NCT07351045 is the pure-obesity trial (2,000 participants, placebo-controlled, Hoffmann-La Roche sponsor); NCT07351058 is the obesity-with-T2D trial (1,600 participants). [6][7] Both use once-weekly subcutaneous dosing. The 72-week window is the regulatory standard for weight-loss trials, long enough to show whether the drug plateaus or keeps working, and long enough for payers to see durable benefit. Combined enrollment above 3,600 patients matches what Novo and Lilly have run and signals Roche is treating this as a flagship launch rather than a hedge. The design is cleaner than most pipeline programs: endpoint is objective (weight on a scale), measurement is non-invasive, and the comparator is placebo, so success does not depend on a head-to-head showdown. One gap: Roche has not yet publicly disclosed a dedicated cardiovascular outcomes trial for enicepatide, which Novo ran for semaglutide (SELECT) and which is becoming a payer and regulator expectation for the class. [13]

Our model estimates a 22% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 35%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual, larger-than-typical enrollment for this phase, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is low on binary success (will it cause weight loss) but high on commercial threshold (will it beat tirzepatide). The Phase 1b ~18.8% at 24 weeks is competitive, but tirzepatide delivered mean body weight reduction of 20.9% at 72 weeks in the SURMOUNT-1 15 mg arm (ITT). [15] Enicepatide has to at least match that in Phase 3 to realistically displace Zepbound at the formulary level. Safety risk is primarily class-wide: GLP-1 drugs cause nausea, vomiting, diarrhea, gallbladder events, and rare pancreatitis, and the FDA added a boxed warning for medullary thyroid carcinoma to the class based on rodent data. [16] No off-target signals specific to enicepatide have surfaced publicly. Execution risk includes manufacturing: GLP-1 drugs have been supply-constrained industry-wide, and Roche does not have the fill-finish capacity Lilly has built out for tirzepatide. [10] Oral GLP-1 competition is the under-appreciated risk: Lilly's orforglipron (oral, non-peptide GLP-1 agonist) is in Phase 3 with obesity readouts expected 2025-2026, and Novo is advancing high-dose oral semaglutide for obesity on top of the already-approved T2D form (Rybelsus). [19][20] A once-weekly injectable launching in 2028-2029 into a market with approved orals faces a materially tougher formulary position than the current injectable-only landscape implies. Commercial risk is the hardest to size. Even with a clean Phase 3 win, enicepatide enters a market where Lilly and Novo have multi-year head starts, direct-pay distribution, and payer formulary lock-in. The FDA's resolution of the semaglutide and tirzepatide shortages ended the legal basis for most compounding pharmacy production, which protects branded pricing but removed a cheap on-ramp that had been driving category growth. [21] Pricing pressure is coming: Lilly already sells Zepbound vials at $499/month cash, and any Medicare coverage expansion will come with price concessions. [17] IP exclusivity is a first-order commercial question that Roche has not publicly detailed for enicepatide; Carmot's composition-of-matter and formulation patents were a core component of the $2.7B acquisition rationale, but specific expiry dates have not been disclosed in filings reviewed, and biosimilar semaglutide is already a near-term policy topic. Enicepatide needs to be either meaningfully better on efficacy, meaningfully better on tolerability, or meaningfully cheaper, and probably at least two of the three.

Worth watching, with specific anchor points. Phase 2 trials have completed per the registry, so topline Phase 2 numbers are the next material public data point and the lack of disclosure to date is a mild negative. If the obesity Phase 2 readout holds in the 18-22% weight-loss range at 48 weeks, Roche has a credible challenger and the readthrough to Amgen and Lilly is positive. If it drops below 15%, enicepatide becomes a hedge rather than a flagship, and investor attention rotates back to retatrutide, MariTide, and orforglipron. Phase 3 topline readouts realistically land in 2027. The commercial question through 2026 is whether Roche signals aggressive manufacturing investment and ex-US regulatory strategy, both of which separate serious launches from token entries. Roche's 2024 pharmaceuticals division sales were approximately CHF 44.5B (~$50B USD), with total group sales of roughly CHF 60.5B - not the ~$72B figure sometimes conflated across currency bases, but still enough balance sheet to go hard. [18] Historically Roche has been slower than Lilly or Novo in building direct-pay distribution and consumer-facing digital infrastructure. Carmot's broader pipeline (CT-996 oral GLP-1 small molecule, CT-868 GLP-1/GIP/GCG triple agonist) is also now Roche's and could matter more than enicepatide alone if the oral delivery trend hardens. The sector readthrough matters: a strong enicepatide readout further validates GLP-1/GIP and compresses the valuation gap for Amgen (MariTide) and Lilly (retatrutide). A weak readout hurts Roche but not the mechanism, since tirzepatide's data is already locked in. Check back on Phase 2 topline (expected late 2026 or early 2027), on orforglipron Phase 3 readouts, and on any Roche R&D day commentary on obesity manufacturing capacity and IP exclusivity.

Clinical trial records (NCT06628362, NCT06525935, NCT07351045, NCT07351058, NCT07626515), Roche press releases on the Carmot acquisition and CT-388 Phase 1b data, Lilly SURMOUNT and SURPASS program publications (Jastreboff NEJM 2022), Novo Nordisk STEP and SELECT publications, Lilly and Roche annual financial filings, Lilly orforglipron ACHIEVE/ATTAIN Phase 3 program disclosures, FDA 2025 compounding enforcement rulings on semaglutide and tirzepatide.